A detailed history of Advisor Group Holdings, Inc. transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 900 shares of CTMX stock, worth $1,016. This represents 0.0% of its overall portfolio holdings.

Number of Shares
900
Previous 900 -0.0%
Holding current value
$1,016
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.21 - $5.13 $1,089 - $4,617
900 New
900 $1,000
Q1 2023

May 12, 2023

SELL
$1.48 - $2.88 $20 - $40
-14 Reduced 0.09%
15,350 $23,000
Q2 2022

Aug 10, 2022

BUY
$1.53 - $2.89 $23,009 - $43,462
15,039 Added 4627.38%
15,364 $28,000
Q1 2022

May 04, 2022

BUY
$2.67 - $4.68 $827 - $1,450
310 Added 2066.67%
325 $1,000
Q3 2021

Nov 05, 2021

SELL
$4.32 - $6.43 $133 - $199
-31 Reduced 67.39%
15 $0
Q2 2021

Aug 02, 2021

BUY
$6.33 - $9.91 $291 - $455
46 New
46 $0

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $74.5M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.